Clinical Trials

Because your heart matters

Cardior HF-REVERT patients

Cardior’s clinical trials addressing heart failure

Myocardial infarction (MI), commonly known as a heart attack, is an extremely severe condition caused by a blockage in the coronary arteries limiting the blood supply to the heart. Even if resolved, MI can lead to permanent damage of the heart initiating pathological cardiac remodeling resulting in the development of heart failure. Heart failure remains one of the leading causes of death globally with only limited treatment options affecting patients’ and their families’ quality of life.

Cardior clinical study

CDR132L, Cardior’s lead compound, is designed to halt and reverse detrimental cardiac remodeling following myocardial infarction (MI) as the first-ever ncRNA-based therapy to enter clinical trials in heart disease. It is currently being investigated in the Phase 2 HF-REVERT clinical trial (NCT05350969) in 280 post-MI patients with cardiac dysfunction at more than 60 locations across Europe.

Data from our Phase 1b study, published in European Heart Journal, showed a favorable safety profile and beneficial cardiac effects in heart failure patients treated with CDR132L, as compared to placebo (NCT04045405).

Novo Nordisk logo
Effective 2 May 2024,
Cardior Pharmaceuticals is a wholly-owned subsidiary
of Novo Nordisk Region Europe A/S

This will close in 0 seconds